- Seattle, Washington
- The leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.
- Chad Robins, Harlan Robins, Christopher Carlson
- Therapeutics, Health Care, Biotechnology
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.
We bring the accuracy and sensitivity of our immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. We are also committed to translating immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.
Funding Rounds (7) - $406.8MUpdate
|Date||Amount / Round||Valuation||Lead Investor||Investors|
|May, 2015||$195M / Series F||—||Matrix Capital Management||4|
|Jan, 2015||$94M / Series E||—||—||0|
|Apr, 2014||$100M / Series D||—||Viking Global Investors||1|
|Apr, 2014||$5M / Series C||—||Viking Global Investors||1|
|Sep, 2013||$2.5M / Grant||—||—||0|
|Jun, 2011||$5.8M / Series B||—||—||0|
|May, 2010||$4.5M / Venture||—||—||0|
Current Team (11)Update
1551 Eastlake Ave E
Seattle, Washington 98102